Nitroxyl (HNO) reduces endothelial and monocyte activation and promotes M2 macrophage polarization.

Nitroxyl anion (HNO) donors are currently being assessed for their therapeutic utility in several cardiovascular disorders including heart failure. Here, we examine their effect on factors that precede atherosclerosis including endothelial cell and monocyte activation, leucocyte adhesion to the endothelium and macrophage polarization. Similar to the NO donor glyceryl trinitrate (GTN), the HNO donors Angeli's salt (AS) and isopropylamine NONOate (IPA/NO) decreased leucocyte adhesion to activated human umbilical vein endothelial cells (HUVECs) and mouse isolated aorta. This reduction in adhesion was accompanied by a reduction in intercellular adhesion molecule-1 (ICAM-1) and the cytokines monocyte chemoattractant protein 1 (MCP-1) and interleukin 6 (IL-6) which was inhibitor of nuclear factor κB (NFκB) α (IκBα)- and subsequently NFκB-dependent. Intriguingly, the effects of AS on leucocyte adhesion, like those on vasodilation, were found to not be susceptible to pharmacological tolerance, unlike those observed with GTN. As well, HNO reduces monocyte activation and promotes polarization of M2 macrophages. Taken together, our data demonstrate that HNO donors can reduce factors that are associated with and which precede atherosclerosis and may thus be useful therapeutically. Furthermore, since the effects of the HNO donors were not subject to tolerance, this confers an additional advantage over NO donors.

[1]  G. Jennings,et al.  Compound 21, a selective agonist of angiotensin AT2 receptors, prevents endothelial inflammation and leukocyte adhesion in vitro and in vivo , 2016, British journal of pharmacology.

[2]  K. Andrews,et al.  Nitroxyl: a vasodilator of human vessels that is not susceptible to tolerance. , 2015, Clinical science.

[3]  T. Münzel,et al.  Organic nitrates: update on mechanisms underlying vasodilation, tolerance and endothelial dysfunction. , 2014, Vascular pharmacology.

[4]  D. Kass,et al.  Nitroxyl (HNO): A Novel Approach for the Acute Treatment of Heart Failure , 2013, Circulation. Heart failure.

[5]  C. Sobey,et al.  Nitroxyl (HNO) suppresses vascular Nox2 oxidase activity. , 2013, Free radical biology & medicine.

[6]  T. Münzel,et al.  Nitrate therapy and nitrate tolerance in patients with coronary artery disease. , 2013, Current opinion in pharmacology.

[7]  F. Zouein,et al.  Acyloxy Nitroso Compounds Inhibit LIF Signaling in Endothelial Cells and Cardiac Myocytes: Evidence That STAT3 Signaling Is Redox-Sensitive , 2012, PloS one.

[8]  O. Lunov,et al.  Thioredoxin-1 Promotes Anti-Inflammatory Macrophages of the M2 Phenotype and Antagonizes Atherosclerosis , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[9]  P. Meikle,et al.  Caveolin-1 Plays a Critical Role in the Differentiation of Monocytes into Macrophages , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[10]  C. Sobey,et al.  Vasorelaxant and antiaggregatory actions of the nitroxyl donor isopropylamine NONOate are maintained in hypercholesterolemia. , 2011, American journal of physiology. Heart and circulatory physiology.

[11]  K. Andrews,et al.  Imaging Leukocyte Adhesion to the Vascular Endothelium at High Intraluminal Pressure , 2011, Journal of visualized experiments : JoVE.

[12]  W. Gorczyca,et al.  Nitric oxide affects IL-6 expression in human peripheral blood mononuclear cells involving cGMP-dependent modulation of NF-κB activity. , 2011, Cytokine.

[13]  E. Capes,et al.  Ryanodine receptors , 2011, Skeletal Muscle.

[14]  Mohamed Amine Bouhlel,et al.  Human Atherosclerotic Plaque Alternative Macrophages Display Low Cholesterol Handling but High Phagocytosis Because of Distinct Activities of the PPAR&ggr; and LXR&agr; Pathways , 2011, Circulation research.

[15]  K. Andrews,et al.  Nitroxyl (HNO) as a vasoprotective signaling molecule. , 2011, Antioxidants & redox signaling.

[16]  R. Widdop,et al.  Chronic administration of the HNO donor Angeli's salt does not lead to tolerance, cross-tolerance, or endothelial dysfunction: comparison with GTN and DEA/NO. , 2011, Antioxidants & redox signaling.

[17]  Nick D. Tsihlis,et al.  Isopropylamine NONOate (IPA/NO) moderates neointimal hyperplasia following vascular injury. , 2010, Journal of vascular surgery.

[18]  R. Bartlett,et al.  The attenuation of platelet and monocyte activation in a rabbit model of extracorporeal circulation by a nitric oxide releasing polymer. , 2010, Biomaterials.

[19]  S. Del Turco,et al.  Prominent role of NF-kappaB in the induction of endothelial activation by endogenous nitric oxide inhibition. , 2009, Nitric oxide : biology and chemistry.

[20]  J. Hansen,et al.  Soluble Guanylate Cyclase Agonists Inhibit Expression and Procoagulant Activity of Tissue Factor , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[21]  K. Andrews,et al.  A role for nitroxyl (HNO) as an endothelium‐derived relaxing and hyperpolarizing factor in resistance arteries , 2009, British journal of pharmacology.

[22]  R. Widdop,et al.  Nitroxyl Anion Donor, Angeli’s Salt, Does Not Develop Tolerance in Rat Isolated Aortae , 2007, Hypertension.

[23]  B. Kemp-Harper,et al.  The nitroxyl anion (HNO) is a potent dilator of rat coronary vasculature. , 2007, Cardiovascular research.

[24]  M. Zaccolo,et al.  Nitroxyl Improves Cellular Heart Function by Directly Enhancing Cardiac Sarcoplasmic Reticulum Ca2+ Cycling , 2007, Circulation Research.

[25]  S. Moncada,et al.  Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  B. Kemp-Harper,et al.  NO‐ Activates Soluble Guanylate Cyclase and Kv Channels to Vasodilate Resistance Arteries , 2003, Hypertension.

[27]  D. Wink,et al.  Ingress and reactive chemistry of nitroxyl-derived species within human cells. , 2002, Free radical biology & medicine.

[28]  C. Triggle,et al.  Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide andnitroxyl ion , 2001, British journal of pharmacology.

[29]  A. Hishida,et al.  Dexamethasone attenuates neutrophil infiltration in the rat kidney in ischemia/reperfusion injury: the possible role of nitroxyl. , 2001, Free radical biology & medicine.

[30]  K. Houk,et al.  On the acidity and reactivity of HNO in aqueous solution and biological systems , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Rand,et al.  Differential actions of L‐cysteine on responses to nitric oxide, nitroxyl anions and EDRF in the rat aorta , 2000, British journal of pharmacology.

[32]  J. Liao,et al.  Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants , 1998, Journal of leukocyte biology.

[33]  J. Liao,et al.  Inhibition of Endothelial Vascular Cell Adhesion Molecule-1 Expression by Nitric Oxide Involves the Induction and Nuclear Translocation of IκBα* , 1997, The Journal of Biological Chemistry.

[34]  D. Harrison,et al.  Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Zamora,et al.  Oxidative release of nitric oxide accounts for guanylyl cyclase stimulating, vasodilator and anti-platelet activity of Piloty's acid: a comparison with Angeli's salt. , 1995, The Biochemical journal.

[36]  P. Libby,et al.  Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. , 1995, The Journal of clinical investigation.

[37]  T. Maniatis,et al.  Transcriptional regulation of endothelial cell adhesion molecules: NF‐κB and cytokine‐inducible enhancers , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  R. Busse,et al.  Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. , 1995, Circulation research.

[39]  M. Feelisch,et al.  Bioassay discrimination between nitric oxide (NO.) and nitroxyl (NO-) using L-cysteine. , 1994, Biochemical and biophysical research communications.

[40]  L. Ignarro,et al.  Conversion of nitroxyl (HNO) to nitric oxide (NO) in biological systems: the role of physiological oxidants and relevance to the biological activity of HNO. , 1993, Biochemical and biophysical research communications.

[41]  M. Rand,et al.  EFFECTS OF HYDROXOCOBALAMIN AND HAEMOGLOBIN ON NO‐MEDIATED RELAXATIONS IN THE RAT ANOCOCCYGEUS MUSCLE , 1993, Clinical and experimental pharmacology & physiology.

[42]  P. Kubes,et al.  Nitric oxide: an endogenous modulator of leukocyte adhesion. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[43]  G. Salama,et al.  Nitroxyl triggers Ca2+ release from skeletal and cardiac sarcoplasmic reticulum by oxidizing ryanodine receptors. , 2005, Cell calcium.